endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.62751/2713-0177-2024-5-4-16endofocus-125Research ArticleОБЗОР ЛИТЕРАТУРЫLITERATURE REVIEWДолгосрочная эффективность метформина и первичная профилактика осложнений сахарного диабета 2 типа: результаты 42-летнего наблюдения UKPDSLong-term efficacy of metformin and primary prevention of complications of type 2 diabetes mellitus: Results from 42-year UKPDS follow-uphttps://orcid.org/0000-0001-5512-6899УшановаФ. О.UshanovaF. O.

Ушанова Фатима Омариевна – к.м.н., доцент кафедры эндокринологии ИКМ 

Москва

Fatima O. Ushanova – C. Sci. (Med.)

Moscow

fati_2526@mail.ruhttps://orcid.org/0009-0008-9443-3961ИзмайловаТ. Я.IzmailovaT. Ya.

Измайлова Тамара Ярагиевна – студентка

Москва

Tamara Y. Izmailova – student 

Moscow

БогачеваТ. Л.BogachevaT. L.

Богачева Татьяна Леонидовна – ассистент кафедры эндокринологии ИКМ

Москва

Tatyana L. Bogacheva – assistant

Moscow

bogacheva@68gkb.ruФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава РоссииPirogov Russian National Research Medical UniversityФГБОУ ВО «Российский университет медицины» Минздрава РоссииRussian University of Medicine of the Ministry of Health of the Russian Federation202425122024542834Copyright © Ушанова Ф.О., Измайлова Т.Я., Богачева Т.Л., 20252025Ушанова Ф.О., Измайлова Т.Я., Богачева Т.Л.Ushanova F.O., Izmailova T.Y., Bogacheva T.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/125

Метформин, являющийся одним из основных препаратов для лечения сахарного диабета 2 типа (СД2), недавно получил новое подтверждение своей эффективности. Результаты 24-летнего наблюдения за пациентами, завершившими участие в 20-летнем исследовании UKPDS, продемонстрировали значительное преимущество раннего назначения этого лекарственного средства в предотвращении осложнений диабета. В наблюдение были включены 1489 пациентов со средним возрастом 70,9 лет. По истечении 42 лет наблюдения после рандомизации в UKPDS в группе метформина сохранялось численное преимущество в профилактике исходов СД2 по сравнению с группой препаратов сульфонилмочевины / инсулина: любого исхода, связанного с СД (18 против 10%), смерти, связанной с СД (25 против 16%), смерти от любых причин (20 против 10%), инфаркта миокарда (31 против 17%). Эти результаты статистически значимо отличались от группы диетотерапии (p <0,05). Таким образом, у метформина обнаружено первичное профилактическим действие на исходы СД2, которое сохраняется на протяжении практически всей жизни пациента с этим заболеванием.

Metformin, long considered a mainstay of treatment for type 2 diabetes mellitus (T2DM), has recently received new evidence of its effectiveness. Results from a 24-year follow-up of patients who completed the 20-year UKPDS study have demonstrated a significant benefit of early metformin administration in preventing diabetes complications. The extension study included 1489 patients with a mean age of 70.9 years. After 42 years of follow-up after randomization in the UKPDS, the metformin group retained a numerical advantage in preventing T2DM outcomes compared with the sulfonylurea/insulin group: any outcome related to DM (18% vs. 10%), death related to DM (25% vs. 16%), death from any cause (20% vs. 10%), myocardial infarction (31% vs. 17%). These results were significantly different from the diet therapy group (p <0.05). Thus, metformin was found to have a primary preventive effect on the outcomes of T2DM, which persists throughout almost the entire life of the patient with this disease.

метформинUKPDSсахарный диабет 2 типакардиоваскулярные заболеванияинфаркт миокардасмертьпрофилактикаmetforminUKPDStype 2 diabetes mellituscardiovascular diseasemyocardial infarctiondeathpreventionReferencesTriggle CR, Mohammed I, Bshesh K et al. Metformin: Is it a drug for all reasons and diseases? Metabolism. 2022; 133: 155223. doi: 10.1016/j.metabol.2022.155223.Triggle CR, Mohammed I, Bshesh K et al. Metformin: Is it a drug for all reasons and diseases? Metabolism. 2022; 133: 155223. doi: 10.1016/j.metabol.2022.155223.Vieira IH, Barros LM, Baptista CF et al. Recommendations for practical use of metformin, a central pharmacological therapy in type 2 diabetes. Clinical Diabetes. 2022; 40(1): 97–107. doi: 10.2337/cd21-0043.Vieira IH, Barros LM, Baptista CF et al. Recommendations for practical use of metformin, a central pharmacological therapy in type 2 diabetes. Clinical Diabetes. 2022; 40(1): 97–107. doi: 10.2337/cd21-0043.Cefalu WT, Kaul S, Gerstein HC et al. Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care. 2017; 41(1): 14–31. doi: 10.2337/dci17-0057.Cefalu WT, Kaul S, Gerstein HC et al. Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care. 2017; 41(1): 14–31. doi: 10.2337/dci17-0057.Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–89. doi: 10.1056/NEJMoa0806470.Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577–89. doi: 10.1056/NEJMoa0806470.Holman R. for the UKPDS Group. A brief history of the UK Prospective Diabetes Study. Br J Diabetes. 2022; 22(Suppl 1): S32–35. doi: 10.15277/bjd.2022.359.Holman R. for the UKPDS Group. A brief history of the UK Prospective Diabetes Study. Br J Diabetes. 2022; 22(Suppl 1): S32–35. doi: 10.15277/bjd.2022.359.Мельникова О.Г. Британское проспективное исследование сахарного диабета (UKPDS) – результаты 30-летнего наблюдения больных сахарным диабетом 2 типа. Сахарный диабет. 2008; (4): 91–92. doi: 10.14341/2072-0351-5599.Мельникова О.Г. Британское проспективное исследование сахарного диабета (UKPDS) – результаты 30-летнего наблюдения больных сахарным диабетом 2 типа. Сахарный диабет. 2008; (4): 91–92. doi: 10.14341/2072-0351-5599.Leslie RD. United Kingdom prospective diabetes study (UKPDS): What now or so what? Diabetes Metab Res Rev. 1999; 15(1): 65–71. doi: 10.1002/(sici)1520-7560(199901/02)15:13.0.co;2-x.Leslie RD. United Kingdom prospective diabetes study (UKPDS): What now or so what? Diabetes Metab Res Rev. 1999; 15(1): 65–71. doi: 10.1002/(sici)1520-7560(199901/02)15:13.0.co;2-x.Adler AI, Coleman RL, Leal J et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024; 404(10448): 145–55. doi: 10.1016/S0140-6736(24)00537-3.Adler AI, Coleman RL, Leal J et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024; 404(10448): 145–55. doi: 10.1016/S0140-6736(24)00537-3.Fitzpatrick T, Perrier L, Shakik S et al. Assessment of long-term follow-up of randomized trial participants by linkage to routinely collected data. JAMA Netw Open. 2018; 1(8): e186019. doi: 10.1001/jamanetworkopen.2018.6019.Fitzpatrick T, Perrier L, Shakik S et al. Assessment of long-term follow-up of randomized trial participants by linkage to routinely collected data. JAMA Netw Open. 2018; 1(8): e186019. doi: 10.1001/jamanetworkopen.2018.6019.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837–53.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837–53.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317(7160): 703–13.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317(7160): 703–13.Holman RR, Paul SK, Bethel MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008; 359(15): 1565–76. doi: 10.1056/NEJMoa0806359.Holman RR, Paul SK, Bethel MA et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008; 359(15): 1565–76. doi: 10.1056/NEJMoa0806359.Folz R, Laiteerapong N. The legacy effect in diabetes: Are there long-term benefits? Diabetologia. 2021; 64(10): 2131–37. doi: 10.1007/s00125-021-05539-8.Folz R, Laiteerapong N. The legacy effect in diabetes: Are there long-term benefits? Diabetologia. 2021; 64(10): 2131–37. doi: 10.1007/s00125-021-05539-8.Giaccari A, Solini A, Frontoni S et al. Metformin benefits: Another example for alternative energy substrate mechanism? Diabetes Care. 2021; 44(3): 647–54. doi: 10.2337/dc20-1964.Giaccari A, Solini A, Frontoni S et al. Metformin benefits: Another example for alternative energy substrate mechanism? Diabetes Care. 2021; 44(3): 647–54. doi: 10.2337/dc20-1964.Hattori Y, Suzuki K, Hattori S et al. Metformin Inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006; 47(6): 1183–88. doi: 10.1161/01.HYP.0000221429.94591.72.Hattori Y, Suzuki K, Hattori S et al. Metformin Inhibits cytokine-induced nuclear factor κB activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension. 2006; 47(6): 1183–88. doi: 10.1161/01.HYP.0000221429.94591.72.Carrillo-Larco RM, Guzman-Vilca WC, Xu X et al. Mean age and body mass index at type 2 diabetes diagnosis: Pooled analysis of 56 health surveys across income groups and world regions. Diabet Med. 2024; 41(2): e15174. doi: 10.1111/dme.15174.Carrillo-Larco RM, Guzman-Vilca WC, Xu X et al. Mean age and body mass index at type 2 diabetes diagnosis: Pooled analysis of 56 health surveys across income groups and world regions. Diabet Med. 2024; 41(2): e15174. doi: 10.1111/dme.15174.Dedov II, Shestakova MV, Vikulova OK et al. Diabetes mellitus in the Russian Federation: Dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023; 26(2): 104–23. doi: 10.14341/DM13035-10291.Dedov II, Shestakova MV, Vikulova OK et al. Diabetes mellitus in the Russian Federation: Dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes mellitus. 2023; 26(2): 104–23. doi: 10.14341/DM13035-10291.Mannucci E, Silverii GA. Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention. Diabetes Obes Metab. 2023; 25(12): 3435–43. doi: 10.1111/dom.15226.Mannucci E, Silverii GA. Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: An evidence-based approach to the categories of primary and secondary prevention. Diabetes Obes Metab. 2023; 25(12): 3435–43. doi: 10.1111/dom.15226.

The authors declare that there are no conflicts of interest present.